Compare Camurus AB with Similar Stocks
Dashboard
1
Flat results in Mar 26
- INTEREST(HY) At SEK 3.04 MM has Grown at 88.02%
- DEBTORS TURNOVER RATIO(HY) Lowest at 3.48 times
- PRE-TAX PROFIT(Q) At SEK 183.86 MM has Fallen at -21.18%
2
With ROE of 17.37%, it has a expensive valuation with a 6.67 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SEK 33,924 Million (Mid Cap)
38.00
NA
0.00%
-0.87
17.37%
8.01
Revenue and Profits:
Net Sales:
533 Million
(Quarterly Results - Mar 2026)
Net Profit:
144 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.45%
0%
21.45%
6 Months
-9.73%
0%
-9.73%
1 Year
-7.52%
0%
-7.52%
2 Years
-6.09%
0%
-6.09%
3 Years
90.37%
0%
90.37%
4 Years
184.86%
0%
184.86%
5 Years
171.04%
0%
171.04%
Camurus AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
46.47%
EBIT Growth (5y)
44.33%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
0.68
Tax Ratio
22.81%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
53.15%
ROE (avg)
8.72%
Valuation key factors
Factor
Value
P/E Ratio
38
Industry P/E
Price to Book Value
6.67
EV to EBIT
27.74
EV to EBITDA
26.97
EV to Capital Employed
46.31
EV to Sales
10.83
PEG Ratio
0.56
Dividend Yield
NA
ROCE (Latest)
166.96%
ROE (Latest)
17.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
533.10
464.50
14.77%
Operating Profit (PBDIT) excl Other Income
187.70
125.30
49.80%
Interest
1.50
1.60
-6.25%
Exceptional Items
0.00
0.00
Consolidate Net Profit
143.80
100.90
42.52%
Operating Profit Margin (Excl OI)
339.20%
255.50%
8.37%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 14.77% vs -18.09% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 42.52% vs -47.61% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,265.40
1,867.60
21.30%
Operating Profit (PBDIT) excl Other Income
907.40
483.60
87.63%
Interest
5.80
1.10
427.27%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
735.60
428.40
71.71%
Operating Profit Margin (Excl OI)
390.30%
252.00%
13.83%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 21.30% vs 8.78% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 71.71% vs -0.70% in Dec 2024
About Camurus AB 
Camurus AB
Pharmaceuticals & Biotechnology
Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
Company Coordinates 
Company Details
Solvegatan 41 , LUND None : 223 62
Registrar Details






